S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, K. | - |
dc.contributor.author | Yun, S-T | - |
dc.contributor.author | Yun, C-O | - |
dc.contributor.author | Ahn, B-Y | - |
dc.contributor.author | Jo, E-C | - |
dc.date.accessioned | 2021-09-06T14:58:06Z | - |
dc.date.available | 2021-09-06T14:58:06Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2012-10 | - |
dc.identifier.issn | 0969-7128 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/107325 | - |
dc.description.abstract | S100A2, a member of the S100 family of calcium-binding proteins, has been implicated in carcinogenesis as both a tumor suppressor and stimulator. Here, we characterized promoter activity of S100A2, generated an S100A2 promoter-driven conditionally replicative adenovirus (Ad/SA), and evaluated its anti-tumor activity in vitro and in vivo. Promoter activity of S100A2 was greatly restricted to tumor cells, and the S100A2 promoter bound with typical nuclear targets of epidermal growth factor receptor (EGFR) signaling. EGF-stimulated EGFR phosphorylation induced S100A2 expression and further activated E1A expression of Ad/SA, which was restored by EGFR signal inhibition in a concentration-dependent manner in non-small-cell lung carcinoma (NSCLC). In two EGFR-activated tumor xenograft animal models, Ad/SA exhibited potent anti-tumor activity, whereas cetuximab, an EGFR-targeting anticancer drug, was active transiently or ineffective. Combined treatment with cetuximab or cisplatin plus Ad/SA resulted in enhanced anti-tumor activity. Immunohistochemical analysis of tumor sections showed moderate-to-high grade signals for EGFR and adenovirus, and a reduction in viable cells in Ad/SA-treated tumors. Collectively, these results demonstrate that the S100A2 promoter-driven adenovirus is a potent inhibitor of cancers, and further suggest that S100A2 is a target gene of EGFR signaling pathway in NSCLC. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | CALCIUM-BINDING PROTEINS | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | TUMOR-SUPPRESSOR | - |
dc.subject | PANCREATIC-CANCER | - |
dc.subject | PROSTATE-CANCER | - |
dc.subject | BREAST-CANCER | - |
dc.subject | GENE S100A2 | - |
dc.subject | STAGE-I | - |
dc.subject | EXPRESSION | - |
dc.subject | CHEMOTHERAPY | - |
dc.title | S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, B-Y | - |
dc.identifier.doi | 10.1038/gt.2011.168 | - |
dc.identifier.scopusid | 2-s2.0-84867400153 | - |
dc.identifier.wosid | 000309809800002 | - |
dc.identifier.bibliographicCitation | GENE THERAPY, v.19, no.10, pp.967 - 977 | - |
dc.relation.isPartOf | GENE THERAPY | - |
dc.citation.title | GENE THERAPY | - |
dc.citation.volume | 19 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 967 | - |
dc.citation.endPage | 977 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | CALCIUM-BINDING PROTEINS | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | TUMOR-SUPPRESSOR | - |
dc.subject.keywordPlus | PANCREATIC-CANCER | - |
dc.subject.keywordPlus | PROSTATE-CANCER | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | GENE S100A2 | - |
dc.subject.keywordPlus | STAGE-I | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordAuthor | S100A2 promoter | - |
dc.subject.keywordAuthor | epidermal growth factor receptor signaling | - |
dc.subject.keywordAuthor | conditionally replicative adenovirus | - |
dc.subject.keywordAuthor | non-small-cell lung carcinoma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.